Posted by Michael Wonder on 20 Sep 2021
Abbott receives FDA approval for minimally invasive Portico with Flexnav TAVR system to treat patients with aortic valve disease
20 September 2021 - Transcatheter aortic valve replacement procedure treats people with symptomatic, severe aortic stenosis who are at high or extreme risk for open heart surgery.
Abbott today announced that the U.S. FDA has approved the company's Portico with FlexNav transcatheter aortic valve replacement system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open heart surgery.
